Orion Portfolio Solutions LLC Sells 1,389 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Orion Portfolio Solutions LLC lessened its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 5.8% in the third quarter, HoldingsChannel reports. The firm owned 22,434 shares of the biopharmaceutical company’s stock after selling 1,389 shares during the period. Orion Portfolio Solutions LLC’s holdings in Intra-Cellular Therapies were worth $1,641,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. True Wealth Design LLC acquired a new position in shares of Intra-Cellular Therapies during the 3rd quarter worth about $32,000. Summit Securities Group LLC acquired a new position in Intra-Cellular Therapies during the second quarter valued at approximately $56,000. Capital Performance Advisors LLP bought a new stake in Intra-Cellular Therapies in the third quarter valued at approximately $74,000. CWM LLC raised its holdings in Intra-Cellular Therapies by 83.9% in the second quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 626 shares during the period. Finally, Quarry LP raised its holdings in Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 1,300 shares during the period. Institutional investors own 92.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, October 30th. JPMorgan Chase & Co. increased their price target on Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a report on Monday, November 4th. Morgan Stanley lifted their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada increased their target price on Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price target on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.23.

Intra-Cellular Therapies Trading Down 0.4 %

Shares of ITCI opened at $83.03 on Friday. Intra-Cellular Therapies, Inc. has a 12 month low of $62.78 and a 12 month high of $93.45. The firm has a fifty day simple moving average of $82.44 and a 200 day simple moving average of $76.69. The stock has a market capitalization of $8.80 billion, a price-to-earnings ratio of -95.44 and a beta of 0.95.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The business had revenue of $175.40 million for the quarter, compared to analyst estimates of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company’s quarterly revenue was up 39.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.25) earnings per share. As a group, research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Buying and Selling at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, President Michael Halstead sold 22,869 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.